Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RP-HPLC quantification and separation of isomeric bacosides and exploration of their anti-schizophrenic potential by network pharmacology.

RSC advances·2026
Same author

Biogenic Silver Nanoparticles-Reinforced Carboxymethyl Chitosan-Based Modified Gauze as Multifaceted Wound Care Material.

Macromolecular bioscience·2026
Same author

A new class of indole-based HDAC8 inhibitors as potential anti-lung cancer agents: <i>in silico</i> design, synthesis, biological assessment and binding interaction analysis.

RSC medicinal chemistry·2026
Same author

Spirooxindoles as Disruptors of Preformed Hen Egg White Lysozyme Fibrils as a Model for Neurodegenerative Diseases.

ChemMedChem·2026
Same author

Unlocking the therapeutic potential of HDAC8-degrading PROTACs: progress, challenges, and future directions.

RSC medicinal chemistry·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Jan 7, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.2K

Molecular Frameworks for ERK1/2 Inhibition: Lessons from Synthetic and SAR Explorations.

Venkatesh Muthukumar1,2, Anushka Vashishth1,2, Subashani Maniam2

  • 1Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Hyderabad Campus, Hyderabad 500078, India.

ACS Omega
|January 5, 2026
PubMed
Summary

Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are key targets in cancer therapy. This review details the evolution of ERK1/2 inhibitors, their challenges, and future therapeutic potential.

More Related Videos

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

19.2K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.3K

Related Experiment Videos

Last Updated: Jan 7, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.2K
Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

19.2K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.3K

Area of Science:

  • Molecular Biology
  • Medicinal Chemistry
  • Oncology

Background:

  • Mitogen-activated protein kinase (MAPK) cascade, particularly ERK1/2, regulates vital cellular functions.
  • Aberrant ERK signaling is implicated in cancer and chronic diseases, making ERK1/2 a critical therapeutic target.
  • Small-molecule ERK1/2 inhibitors have advanced from reversible to selective covalent agents.

Purpose of the Study:

  • To provide a comprehensive overview of ERK1/2 inhibitor development.
  • To analyze scaffold evolution, synthetic strategies, and structure-activity relationships (SAR).
  • To discuss clinical challenges and future directions for ERK1/2-targeted cancer therapeutics.

Main Methods:

  • Review of literature on ERK1/2 inhibitors.
  • Analysis of molecular frameworks and pharmacophores (e.g., pyrazolopyridines, imidazopyrazinone).
  • Discussion of synthetic strategies, complexity, and modularity.

Main Results:

  • Significant progress in developing diverse classes of ERK1/2 inhibitors.
  • Identification of key pharmacophores and their SAR.
  • Highlighting challenges including target selectivity, resistance, and combinatorial therapy.

Conclusions:

  • ERK1/2 inhibitors represent a promising area for anticancer drug development.
  • Overcoming challenges in selectivity and resistance is crucial for sustained clinical efficacy.
  • Integration of chemical innovation and biological insight is key for future therapeutic advancements.